NTII: AI 评分 68/100 — AI 分析 (4月 2026)

Neurobiological Technologies, Inc. (NTII) is a biotechnology company based in Emeryville, California, that operates under a plan of liquidation and dissolution. Founded in 1987, it previously focused on developing investigational drugs for human diseases.

Key Facts: AI Score: 68/100 Sector: Healthcare

公司概况

概要：

Neurobiological Technologies, Inc. (NTII) is a biotechnology firm that has transitioned to a liquidation phase, having previously developed investigational drugs aimed at treating human diseases, reflecting a significant shift in its operational focus.

NTII是做什么的？

Neurobiological Technologies, Inc. (NTII) was founded in 1987 and is headquartered in Emeryville, California. The company initially focused on developing investigational drugs aimed at treating various human diseases, contributing to the biotechnology sector's advancements. However, in October 2009, stockholders approved a plan for liquidation and dissolution, marking a significant shift in the company's operational focus. As a result, NTII no longer actively develops or markets any pharmaceutical products. The transition to liquidation indicates that the company is in the process of winding down its operations and distributing any remaining assets to shareholders. Despite its previous role in the biotech industry, the current status of NTII suggests that it is no longer a player in the competitive landscape of drug development. The company’s history reflects the challenges faced by biotechnology firms, particularly in relation to funding, regulatory hurdles, and market competition. As NTII continues through its liquidation process, it is essential for stakeholders to monitor any developments regarding asset distribution and the final resolution of the company's affairs.

NTII的投资论点是什么？

Neurobiological Technologies, Inc. (NTII) currently operates under a plan of liquidation, which significantly alters its investment proposition. The company’s historical profit margin stands at 11.9%, and it has a gross margin of 99.5%, indicative of its past operational efficiency. However, with no active products in development and a market cap of $0.00B, NTII's potential for future growth is severely limited. The liquidation process means that any value for shareholders will depend on the effective management of asset distribution. the may be worth researching implications of NTII's dissolution and the lack of ongoing operations when evaluating any potential for returns. The absence of dividends further emphasizes the company's transition away from a growth-oriented business model, making it crucial for stakeholders to assess the timeline and outcomes of the liquidation process.

NTII在哪个行业运营？

The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a global market size projected to reach $1.5 trillion by 2028, the sector continues to attract interest from investors and stakeholders. However, companies like Neurobiological Technologies, Inc. (NTII) illustrate the risks involved, as many firms face challenges in transitioning from research to marketable products. The competitive landscape includes a myriad of firms, with peers such as ANTH, CMRA, COTQF, FORU, and GBIM, all vying for market share in therapeutic development. The industry's growth is driven by advancements in technology and increasing demand for novel treatments, but the high failure rates of drug development pose ongoing risks.

Biotechnology

Healthcare

NTII有哪些增长机遇？

Growth opportunity 1: As NTII is currently undergoing liquidation, there are no growth opportunities available. The company's focus has shifted entirely to asset distribution and winding down operations, limiting any potential for future growth.
Growth opportunity 2: Unknown.
Growth opportunity 3: Unknown.
Growth opportunity 4: Unknown.
Growth opportunity 5: Unknown.

Profit margin of 11.9% reflects historical operational efficiency, though no active revenue generation occurs.
Gross margin of 99.5% indicates prior high profitability in drug development.
Market capitalization currently stands at $0.00B, reflecting the company's liquidation status.
The company employs only 4 individuals, indicating a minimal operational footprint.
No dividend yield, as the company is in the process of dissolution.

NTII提供哪些产品和服务？

Previously focused on developing investigational drugs for human diseases.
Operated within the biotechnology sector, contributing to drug development.
Transitioned to a plan of liquidation and dissolution approved by stockholders.
No longer actively markets or develops pharmaceutical products.
Headquartered in Emeryville, California, with a minimal employee base.

NTII如何赚钱？

Historically generated revenue through the development and potential commercialization of investigational drugs.
Currently focused on liquidating assets and distributing any remaining value to shareholders.
No ongoing revenue generation as the company has ceased operations.

Previously targeted healthcare providers and patients in need of innovative treatments.
Engaged with pharmaceutical partners for drug development collaborations.
Served investors and shareholders prior to the liquidation process.

Historical expertise in biotechnology and drug development.
Prior intellectual property related to investigational drugs.
Established relationships within the healthcare and pharmaceutical sectors.

NTII的主要风险是什么？

Ongoing: The company is in liquidation, limiting any potential for future growth.
Potential: High risk of total loss for shareholders as assets are liquidated.
Ongoing: Low trading volume may lead to high volatility in share price.

NTII的核心优势是什么？

Historical expertise in biotechnology.
High gross margin of 99.5% from past operations.
Established relationships in the healthcare sector.

NTII的劣势是什么？

Currently in liquidation, ceasing all operations.
No active products or revenue generation.
Very small employee base of only 4 individuals.

NTII有哪些机遇？

Asset liquidation may provide some returns to shareholders.
Potential for acquisition of intellectual property by other firms.

NTII面临哪些威胁？

High failure rates in drug development across the industry.
Market competition from active biotechnology firms.
Regulatory challenges affecting the biotechnology sector.

NTII的竞争对手是谁？

Anthera Pharmaceuticals — Focuses on developing therapies for serious diseases. — (ANTH)
Comera Life Sciences — Works on innovative drug delivery technologies. — (CMRA)
COTI — Develops targeted therapies for cancer. — (COTQF)
Forian Inc. — Provides data analytics solutions for the healthcare sector. — (FORU)
GB Sciences — Engages in the development of cannabis-based therapies. — (GBIM)

Key Metrics

MoonshotScore: 68/100

Company Profile

CEO: John B. Stuppin
Headquarters: EmeryVille, US
Employees: 4
Founded: 1994

AI Insight

AI analysis pending for NTII

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Neurobiological Technologies, Inc. do?

Neurobiological Technologies, Inc. previously focused on developing investigational drugs for the treatment of human diseases. However, as of now, the company operates under a plan of liquidation and dissolution, which means it is no longer actively involved in drug development or commercialization.

What do analysts say about NTII stock?

Analyst consensus on NTII stock is largely neutral, given the company's current status in liquidation. There are no active growth metrics or valuation considerations, as the focus has shifted to asset distribution rather than ongoing operations.

What are the main risks for NTII?

The primary risks for Neurobiological Technologies, Inc. include the ongoing liquidation process, which limits any potential for future growth, and the possibility of total loss for shareholders as the company winds down its operations. Additionally, low trading volume may result in significant price volatility.